People s United Financial Inc. Has $728,000 Holdings in Hologic, Inc. (HOLX)
People s United Financial Inc. raised its stake in Hologic, Inc. (NASDAQ:HOLX) by 14.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,039 shares of the medical equipment provider’s stock after acquiring an additional 2,071 shares during the period. People s United Financial Inc.’s holdings in Hologic were worth $728,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in HOLX. HealthCor Management L.P. bought a new stake in Hologic in the second quarter valued at $76,604,000. Columbus Circle Investors bought a new stake in Hologic in the second quarter valued at $54,511,000. Vanguard Group Inc. grew its position in Hologic by 4.2% in the second quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock valued at $1,340,850,000 after acquiring an additional 1,200,825 shares during the period. Victory Capital Management Inc. grew its position in Hologic by 23.7% in the second quarter. Victory Capital Management Inc. now owns 5,012,352 shares of the medical equipment provider’s stock valued at $227,461,000 after acquiring an additional 961,528 shares during the period. Finally, Russell Investments Group Ltd. grew its position in Hologic by 229.7% in the second quarter. Russell Investments Group Ltd. now owns 1,059,586 shares of the medical equipment provider’s stock valued at $48,100,000 after acquiring an additional 738,215 shares during the period. Hedge funds and other institutional investors own 96.38% of the company’s stock.
Hologic, Inc. (HOLX) opened at 37.78 on Thursday. The stock’s 50 day moving average price is $37.79 and its 200 day moving average price is $42.16. Hologic, Inc. has a 52 week low of $35.15 and a 52 week high of $46.80. The firm has a market cap of $10.60 billion, a price-to-earnings ratio of 14.07 and a beta of 0.91.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. The business had revenue of $806.10 million for the quarter, compared to analyst estimates of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. Hologic’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS. On average, equities research analysts predict that Hologic, Inc. will post $2.01 EPS for the current year.
A number of brokerages have weighed in on HOLX. Piper Jaffray Companies reiterated a “buy” rating and issued a $51.00 price target on shares of Hologic in a research report on Friday, July 14th. Bank of America Corporation reiterated a “neutral” rating and issued a $48.00 price target (up from $44.00) on shares of Hologic in a research report on Friday, July 21st. Barclays PLC reiterated an “overweight” rating and issued a $53.00 price target (up from $50.00) on shares of Hologic in a research report on Monday, July 17th. Deutsche Bank AG decreased their target price on Hologic from $51.00 to $49.00 and set a “buy” rating on the stock in a report on Thursday, August 3rd. Finally, Royal Bank Of Canada restated a “hold” rating and set a $42.00 target price on shares of Hologic in a report on Friday, September 22nd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $48.38.
In related news, VP Karleen Marie Oberton sold 4,704 shares of the business’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $45.19, for a total transaction of $212,573.76. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Lawrence M. Levy sold 7,139 shares of the business’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $39.04, for a total value of $278,706.56. The disclosure for this sale can be found here. Insiders have sold a total of 18,745 shares of company stock worth $768,189 in the last 90 days. 0.79% of the stock is currently owned by corporate insiders.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.